Slides
Page 1
Investor Deck – Q2 FY27 Oct 22, 2026
Page 2
Certain statements in this release concerning Sagility’s future growth prospects may be seen as forward-looking statements, which involve a number of risks and uncertainties that could cause the actuals to differ materially from such statements. Sagility does not undertake to update any such statement that may have been made from time to time by or on behalf of the company. Safe Harbor
Page 3
▶ 11.9% Y-o-Y Constant currency organic growth in Q2 FY27, driven by expansion within national payers and mid market clients ▶ Won $40.2 M of ACV in Q2 FY27, from 31 existing clients and 1 new logo. Increasing traction seen in larger deals, supported by cross-sell and transformation-led opportunities ▶ Growing AI momentum with new SOW wins, production deployments driving client efficiencies, and AI-led GTM transformation enabling faster solutioning ▶ Acquired Chirok Health LLC to accelerate Provider segment growth. The acquisition adds specialized CDI and coding capabilities, extending Sagility’s end-to-end RCM offering and unlocking new growth opportunities. Performance Highlights Revenue Adjusted EBITDA Adjusted PAT ₹ 20,321 Million US$212.6M ₹ 5,353 Million US $56.0M ₹ 3,254 Million US$34.0M YoY growth % 22.5% 12.2% in CC Margin % 26.3% Margin % 16.0% YoY growth % (Excl. CareSeed) 22.2% YoY growth % 23.0% YoY growth % 8.1% Q2 FY27 Business Insights Rewards & Recognitions Sagility won the Golden Peacock Award for ESG Sagility’s SmarTec Nurse Assist solution won 2026 Stratus Awards for Cloud Computing by Business Intelligence Group in SaaS category 11.9% in CC Revenue Adjusted EBITDA Adjusted PAT ₹ 39,956 Million US$420.4M ₹ 10,069 Million US $105.9M ₹ 5,951 Million US$62.6M YoY growth % 25.0% 13.7% in CC Margin % 25.2% Margin % 14.9% YoY growth % (Excl. CareSeed) 24.7% YoY growth % 25.2% YoY growth % 18.9% H1 FY27 13.4% in CC Sagility India ranked 57 in 100 Best Large Workplaces in Asia 2026 by Great Place to Work®. Recognized amongst Top 10 India’s Best Workplaces for Women 2026 Sagility India earns Great Place To Work® Certification for the second consecutive year Winner of Bronze Stevie® Award in the AI Adoption with Headcount Growth Leader in Avasant’s Healthcare Payer Business Process Transformation 2026 RadarView Interim Dividend ₹0.15 per share Received the Voice of the Customer Honor – HLS Services Specialist
Page 4
KPIs Note: *Adjusted EBITDA represents EBITDA adjusted for earnouts payable under acquisition agreements (DCI, BirchAI , BroadPath & CareSeed), share-based payment awards and excludes other income (including forex gain/loss). **Adjusted PAT reflects EBITDA adjustments excluding other income and FX and adjustments for amortization of intangible assets arising from the carve-out of the healthcare business from HGS, as well as the statutory impact of increase in Minimum wages in Karnataka & Telangana, net of tax ^Voluntary attrition is calculated for employees with tenure exceeding 90 days and presented on an annualized basis, derived from voluntary exits during the respective quarter Q2 FY27 Q1 FY27 Q2 FY26 YoY% H1 FY27 H1 FY26 YoY% Revenue from Operation (in ₹ M) 20,321 19,635 16,585 22.5% 39,956 31,974 25.0% Steady state Revenue 20,321 19,635 16,585 22.5% 39,956 31,974 25.0% Seasonal Revenue (Open Enrollment/AEP) - - - - - - - Revenue by Vertical Split By Payer 89.9% 89.6% 88.5% 89.7% 88.4% By Provider 10.1% 10.4% 11.5% 10.3% 11.6% Growth in revenue from operation (%) 22.5% 27.6% 25.2% 25.0% 25.5% Adjusted EBITDA* (in ₹ M) 5,353 4,716 4,352 23.0% 10,069 8,039 25.2% Adjusted EBITDA % 26.3% 24.0% 26.2% 25.2% 25.1% Adjusted PAT** (in ₹ M) 3,254 2,697 3,010 8.1% 5,951 5,007 18.9% Adjusted PAT % 16.0% 13.7% 18.1% 14.9% 15.7% Total Number of Employees at the end of period 51,486 47,307 44,185 16.5% 51,486 44,185 16.5% Voluntary attrition rate^ (%) 25.7% 28.6% 26.3% 26.6% 26.3%
Page 5
Annual KPIs *Client groups comprise client entities together with their affiliates. **30 clients added via CareSeed acquisition – 26 new client groups, 2 common client groups, 2 affiliates of existing client groups H1 FY27 FY26 FY25 FY24 FY23 Numbers of Client group Active 105 82 75 44 35 Number of new client addition (Gross) 28** 17 38 13 7 Delivery Sites Number of delivery sites 28 31 33 30 27 New site addition (Gross) - 4 10 4 2 TTM Sep26 FY26 FY25 FY24 FY23 Client groups contribution to revenues* Top 3 Client % 60.1% 59.9% 66.2% 68.3% 72.4% Top 5 Client % 70.3% 70.4% 77.9% 79.2% 80.6% Top 10 Client % 84.4% 83.9% 90.5% 91.4% 90.7% Number of Million-dollar client groups Number of clients contributing more than US$ 20M 10 9 7 5 4 Number of clients contributing to US$ 5M - US$ 20M 8 7 6 7 7 Number of clients contributing to US$ 1M - US$ 5M 22 21 12 12 12 Number of clients contributing less than US$ 1M 65 45 50 20 12
Page 6
+ Comprehensive end-to-end Provider RCM solution
Page 7
Chirok strengthens Sagility’s provider footprint Founded in 2020 and headquartered in Nashville, Chirok Health is a specialized provider of Clinical Documentation Improvement (CDI) solutions. The company complements its core CDI offerings with adjacent solutions, including medical coding, RAC, and HEDIS/Stars quality services. US$13 M TTM Sep 2026 revenue 35.8% TTM Sep 2026 Adjusted EBITDA margin 12+ 115%+ Net revenue retention¹ 750+ Employees US$20 M Upfront payment What Chirok adds to Sagility Mid-revenue Cycle expertise CHEMP Workflow platform Provider relationships Specialist talent Prospective, concurrent & retrospective CDI Coding & quality audits Review Validate Audit Provider queries Health systems Physician groups Risk-bearing providers 700+ operations staff Coding, QA & billing India & US delivery Unlocks synergies to broaden Sagility’s provider offering and deliver greater client value Provider Clients (including large hospital systems) 1percentage of recurring revenue retained from existing customer base over a set period, including upgrades/expansions while s ubtracting downgrades/churn. Additionally, contingent consideration up to US$12.35 M payable subject to achievement of specified performance milestones Valuation
Page 8
Chirok bridges the CDI and coding gap, enabling Sagility to offer more comprehensive end-to-end provider revenue solutions Sagility Patient access Chirok core Clinical Documentation & coding Combined scope Billing & claims Sagility Clinical denials & appeals Sagility A/R & collections Chirok rounds out Sagility clinical capabilities across providers and payers, enabling a more complete end-to-end offering. Growth opportunities Deepen provider relationships Health systems and physician groups Cross-sell patient access, denials and collections. Extend CDI and coding into additional specialties. Risk-bearing providers Pair accurate documentation and HCC capture with Sagility’s care management, coordination and outreach. Payer Quality Health plans Combine chart review with HEDIS abstraction and care-gap closure. Support value-based care
Page 9
Marketing & Thought Leadership AI & Intelligent Operations Healthcare Perspectives Research & Insights SmarTec Solutions Advisor, Sasha CoreIQ Operational System of Intelligence Sagility Synchrony Provider Services Claims Lifecycle Case Studies HealthBridge Connect HealthBridge Connect SmarTec Voice Agent SmarTec Voice Agent Blogs CMS-0057-F Compliance CMS-0057-F Compliance Payment Accuracy Across the Claims Lifecycle Payment Accuracy Across the Claims Lifecycle White Paper Future-Proofing Healthcare Payer Operations with Intelligence
Page 10
Financial Highlights
Page 11
Financial Highlights Revenue Adjusted EBITDA Adjusted PAT OCF ₹ 20,321 Million ₹ 5,353 Million ₹ 3,254 Million ₹ 3,182 Million YoY growth 22.5% 12.2% in CC Margin % 26.3% Margin % 16.0% Conversion % 60.6% YoY Growth (Excl. CareSeed) 22.2% 11.9% in CC YoY growth % 23.0% YoY growth % 8.1% DSO 78 days Q2 FY27 H1 FY27 Revenue Adjusted EBITDA Adjusted PAT OCF ₹ 39,956 Million ₹ 10,069 Million ₹ 5,951 Million ₹ 6,343 Million YoY growth 25.0% 13.7% in CC Margin % 25.2% Margin % 14.9% Conversion % 64.9% YoY Growth (Excl. CareSeed) 24.7% 13.4% in CC YoY growth % 25.2% YoY growth % 18.9% DSO 78 days Q2 FY27 revenue grew 22.5% YoY , while adjusted EBITDA margin improved to 26.3%
Page 12
$189.4 $196.8 $197.3 $207.8 $212.6 $25.2 $24.8 26.2% 26.0% 24.9% 24.0% 26.3% Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Adjusted EBITDA Margin Revenue ($M) Steady State Revenue ($M) Seasonal Revenue ($M) Adjusted EBITDA Margin $157.9 $162.3 $171.5 $180.4 $189.4 $9.7 $10.3 26.1% 28.4% 26.6% 24.0% 26.2% Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Adjusted EBITDA Margin Revenue ($M) Revenue Mix and Adjusted EBITDA Margin % Quarterly Seasonality Our Revenues exhibit seasonality. Q3 & Q4 have seasonal Revenues from Open Enrolment and AEP 2 months of BroadPath Revenue ($8.9M) Includes 3 month of BroadPath revenue ($11.3M) Includes CareSeed effective 11th Jun’26 ($0.4M) $181.8 $172.0 $222.0 $222.1
Page 13
Long Term Financial Performance Snapshot 13 Revenue (₹M) (growth % Y-o-Y) FY25 FY26 17.2% 29.1% Adj. EBITDA* (₹M) (growth % Y-o-Y) FY25 FY26 28.4% 23.9% Adj. PAT(₹M) (growth % Y-o-Y) FY25 FY26 37.5% 39.5% Revenue ($M) (growth % Y-o-Y) FY25 FY26 14.9% 23.6% Adj. EBITDA* ($M) (growth % Y-o-Y) FY25 FY26 25.9% 18.7% Adj. PAT ($M) (growth % Y-o-Y) FY25 FY26 34.8% 33.5% *Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI, BroadPath, & CareSeed), share-based payment awards and exclude other income (including forex gain/loss). Consistent Revenue and profitability growth ₹47,536 ₹55,699 ₹71,929 ₹79,910 FY24 FY25 FY26 TTM Sep26 $572.9 $658.3 $814.0 $864.5 FY24 FY25 FY26 TTM Sep26 ₹11,436 ₹14,685 ₹18,200 ₹20,229 FY24 FY25 FY26 TTM Sep26 $137.8 $173.6 $206.0 $218.8 FY24 FY25 FY26 TTM Sep26 $71.1 $95.8 $127.9 $132.6 FY24 FY25 FY26 TTM Sep26 ₹5,896 ₹8,107 ₹11,306 ₹12,250 FY24 FY25 FY26 TTM Sep26
Page 14
Other Financial Indicators 14 ` Adjusted EPS is Adjusted PAT divided by weighted average number of equity shares Adjusted ROCE is Adjusted PAT plus Interest cost divided by capital employed (Assets excluding goodwill and intangibles assets less current liabilities) Net Debt is Borrowing plus lease liabilities less Cash and Cash equivalent including investment in Mutual Fund and Deposits . Borrowing doesn’t include accrued interest Adjusted ROCE continues to be above 50% 1.90x 0.71x 0.11x (0.06)x 1.38 1.76 2.42 2.62 FY24 FY25 FY26 TTM Sep26 Adjusted EPS (in ₹) ₹21,678 ₹10,433 ₹1,962 -₹1,127 -₹5,000 ₹0 ₹5,000 ₹10,000 ₹15,000 ₹20,000 ₹25,000 ₹30,000 FY24 FY25 FY26 TTM Sep26 Net Debt 47.0% 54.9% 58.9% 55.4% FY24 FY25 FY26 TTM Sep26 Adjusted ROCE % 87.2% 89.7% 64.7% 64.9%70.8% 80.5% 54.4% 52.9% FY24 FY25 FY26 H1 FY27 Cash Conversion (%) OCF % FCF %
Page 15
Q2 FY27 Consolidated Profit and Loss Amount in ₹ M *Employee benefits expense excludes M&A earnout and SAR (shown separately under adjustments), ^ Other expenses exclude forex loss, ^^ Other income excludes forex gain. Forex Gain and Forex Loss clubbed together and shown separately. ** Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI, BroadPath & CareSeed), share-based payment awards and exclude other income (including forex gain/loss). Particulars Q2 FY27 Q1 FY27 Q2 FY26 YoY% QoQ% H1 FY27 H1 FY26 YoY% Revenue from Operation 20,321 19,635 16,585 22.5% 3.5% 39,956 31,974 25.0% Steady state Revenue 20,321 19,635 16,585 22.5% 3.5% 39,956 31,974 25.0% Seasonal Revenue (Open Enrollment) - - - - - - - - Employee benefits expense 12,103 12,154 10,070 24,258 19,715 Minimum Wage impact 148 70 - 218 - Other expenses^ 2,717 2,694 2,163 5,411 4,220 Adjusted EBITDA** 5,353 4,716 4,352 23.0% 13.5% 10,069 8,039 25.2% Adjusted EBITDA % 26.3% 24.0% 26.2% 25.2% 25.1% Adjustments M&A Earnouts 27 (8) 127 19 283 SAR (stock appreciation right) – Non Cash 16 60 73 76 145 Other Income^^ 128 143 65 272 115 Forex Gain / (Loss) (186) (283) 516 (469) 566 Reported EBITDA 5,252 4,525 4,733 11.0% 16.1% 9,776 8,293 17.9% Finance costs 185 219 250 404 524 Depreciation and amortisation 1,324 1,280 1,215 2,604 2,397 Profit before Exceptional Items 3,742 3,026 3,268 14.5% 23.7% 6,768 5,372 26.0% Statutory impact of Minimum Wage increase in Karnataka and Telangana - 151 - 151 - Profit Before Tax 3,742 2,875 3,268 14.5% 30.2% 6,617 5,372 23.2% Tax Expenses 900 707 760 1,607 1,378 Reported Profit After Tax 2,842 2,168 2,508 13.3% 31.1% 5,010 3,994 25.4% EPS (₹) 0.61 0.46 0.54 13.3% 31.1% 1.07 0.85 25.4% Adjusted PAT 3,254 2,697 3,010 8.1% 20.6% 5,951 5,007 18.9% Adjusted PAT % 16.0% 13.7% 18.1% 14.9% 15.7% Adjusted EPS (₹) 0.70 0.58 0.64 8.1% 20.6% 1.27 1.07 18.9%
Page 16
Adjustments on EBITDA and PAT 16 Adj A - Earnouts under acquisition agreements and for PAT it is adjusted for tax Adj B - Share based payment awards (non-cash expenses for the company and not tax deductible) Adj C - Amortization of intangible assets (net of tax) that got created due to carveout of healthcare business from HGS & acquisitions Adj D- Exceptional items for Q1 FY27 represents adjustment for increase in past service cost of gratuity and compensated absence on account of increase in minimum wage in K arnataka & Telangana Adj EBITDA Bridge: Q2 FY27 (₹M) Reported EBITDA Adj A Adj B Other income/ FX gain Adjusted EBITDA Adj PAT Bridge: Q2 FY27 (₹M) Reported PAT Adj A Adj B Adj C Adjusted PAT Adj EBITDA Bridge: H1 FY27 (₹M) Reported EBITDA Adj A Adj B Other income/ FX gain Adjusted EBITDA Adj PAT Bridge: H1 FY27 (₹M) Reported PAT Adj A Adj B Adj C Adjusted PATAdj D ₹2,842 ₹20 ₹16 ₹376 ₹3,254 ₹14 ₹76 ₹739 ₹113 ₹5,951 ₹5,010 ₹27 ₹16 ₹58 ₹5,353₹5,252 ₹19 ₹76 ₹198 ₹10,069₹9,776
Page 17
Go Forward Positions Particulars FY26 FY27 FY28 FY29 FY30 FY31 FY32 Closing Debt position 5,670 - - - - - - Debt Repayment 2,350 5,670 - - - - - Interest Payment 543 287 - - - - - Share based Payment awards 122 136 74 39 - - - Earnouts Cost 475 67 96 19 - - - Intangibles Amortisation (A) 1,462 1,580 1,587 1,587 1,587 1,587 1,587 Intangibles Amortisation (B) 392 478 480 398 350 288 254 Debt to be fully repaid in current Financial year Earnout Costs: FY26 includes payouts for DCI, Birch, and BroadPath; FY27 relates to BroadPath and CareSeed; and FY28–FY29 represent CareSeed earnouts only Intangibles Amortization (A) - Amortization of intangible assets that got created due to carveout of healthcare business from HGS Intangibles Amortization (B) - Amortization for intangible assets acquired in relation to acquisitions (DCI, Birch, BroadPath and CareSeed) – Ends by FY36 Amt in ₹ M
Page 18
Balance Sheet – 30th Sep 26 Particulars Sep 26 Mar 26 Property, plant and equipment 4,644 4,624 Right-of-use assets 4,250 4,868 Goodwill 66,085 64,051 Other intangible assets 20,323 20,407 Trade receivables and unbilled 17,753 18,390 Cash and cash equivalents (including investments) 10,068 9,038 Deferred tax assets (net) 1,393 1,514 Other Assets 4,067 3,119 Total Assets 128,583 126,011 Equity 102,281 96,591 Borrowings 4,255 5,776 Lease liabilities 4,765 5,330 Trade payables 2,181 2,217 Deferred tax liabilities (net) 4,149 4,211 Other Liabilities 10,952 11,887 Total Equity & Liabilities 128,583 126,011 Amt in ₹ M
Page 19
Cash Flow – H1 FY27 Particulars H1 FY27 FY26 Profit before tax for the period/ year 6,617 12,389 Adjustment for Non-Operating and Non-Cash items 2,970 5,271 Adjustment for working capital (1,082) (1,895) Income taxes paid (net of refunds) (2,162) (3,735) Net cash flows generated from operating activities (A) - OCF 6,343 12,030 Addition to Fixed Assets (1,168) (1,922) Free Cash flow (FCF) 5,176 10,108 Cash paid for M&A (1,338) - Investment in Mutual fund and Fixed Deposit 843 (5,370) Others 126 185 Net cash flows (used in) investing activities (B) (1,537) (7,107) Repayment of Promoter borrowings (include Interest) (1,719) (2,937) Repayment of lease liabilities (include Interest) (936) (1,843) Dividend paid (468) (234) Net cash flows (used in) financing activities (C) (3,123) (5,014) Net increase/ (decrease) in cash and cash equivalents (A+B+C) 1,683 (91) Cash and cash equivalents at the beginning of the year/period 3,579 3,438 Effect of movement in exchange rates on cash and cash equivalents 61 233 Cash and cash equivalents at the end of the year/ period 5,323 3,579 Net cash flows generated from operating activities % (OCF on Reported EBITDA) 64.9% 64.7% Free Cash flow % (FCF on Reported EBITDA) 52.9% 54.4% Amt in ₹ M
Page 20
Thank you.